What is Xcopri, and how does it work?

Xcopri is a prescription medicine used to treat partial-onset seizures in adults.

It is not known if Xcopri is safe and effective in children.

What are the side effects of Xcopri?

Xcopri may cause serious side effects, including:

  • problems with the electrical system of the heart (QT shortening). Call your healthcare provider if you have symptoms of QT shortening including fast heartbeat (heart palpitations) that last a long time or fainting.
  • nervous system problems. Xcopri may cause problems that can affect your nervous system. Symptoms of nervous system problems include:
    • dizziness
    • trouble walking or with coordination
    • feeling sleepy and tired
    • trouble concentrating, remembering, and thinking clearly
    • vision problems

The most common side effects of Xcopri include:

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Xcopri.

For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Does Xcopri cause addiction or withdrawal symptoms?

Drug Abuse And Dependence

Controlled Substance

Xcopri contains cenobamate and is listed as a Schedule V controlled substance.

Abuse
  • Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. In a human abuse potential study conducted in recreational sedative abusers (n=39), single doses of Xcopri (200 mg and 400 mg) were compared to placebo.
  • Xcopri at single doses of 400 mg produced responses on positive subjective measures such as “Drug Liking,” “Overall Drug Liking,” “Take Drug Again,” and “Good Drug Effects” that were statistically greater than the responses produced on these measures by placebo.
  • In this study, euphoric mood occurred at greater extent with Xcopri (400 mg) (8%) than with placebo (0%).
  • Phase 1 multiple ascending dose studies in healthy subjects showed rates of euphoria and feeling drunk of about 3% and disturbance in attention of about 5% in subjects who received supratherapeutic doses of cenobamate, but these adverse events were absent in the placebo group.
  • In Phase 2 and 3 studies in subjects with epilepsy, euphoric mood, confusional state, and sedation occurred at low rates in subjects who received Xcopri (0.5-2.5%).
Dependence
  • Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.
  • Clinical studies in healthy subjects indicate that Xcopri may cause physical dependence and lead to a withdrawal syndrome characterized by insomnia, decreased appetite, depressed mood, tremor, and amnesia. Xcopri should be withdrawn gradually.

What is the dosage for Xcopri?

Important Administration Instructions

  • Xcopri may be taken any time with or without food. Swallow tablets whole with liquid.
  • Do not crush or chew.

General Dosing Recommendations

Monotherapy And Adjunctive Therapy
  • Xcopri is administered orally once daily.
  • The recommended dosage and titration, which should not be exceeded because of the potential for serious adverse reactions, is included in Table 1.

Table 1: Recommended Dosage for Partial-Onset Seizures in Adults

Initial Dosage
Week 1 and 212.5 mg once daily
Titration Regimen
Week 3 and 425 mg once daily
Week 5 and 650 mg once daily
Week 7 and 8100 mg once daily
Week 9 and 10150 mg once daily
Maintenance Dosage
Week 11 and thereafter200 mg once daily
Maximum Dosage
If needed based on clinical response and tolerability, dose may be increased above 200 mg by increments of 50 mg once daily every two weeks to 400 mg.400 mg once daily

Dosage Modifications In Patients With Hepatic Impairment

  • For patients with mild to moderate (5-9 points on Child-Pugh assessment) hepatic impairment, the maximum recommended dosage is 200 mg once daily.
  • Xcopri is not recommended for use in patients with severe hepatic impairment.

Discontinuation Of Xcopri

  • If Xcopri is discontinued, the dosage should be gradually reduced over a period of at least 2 weeks, unless safety concerns require abrupt withdrawal.

IMAGES

Vascular (Multi-Infarct) Dementia Browse our medical image collection to see examples of MRI brain scans, PET scans, and other imaging techniques used to diagnose and treat brain disorders See Images

What drugs interact with Xcopri?

Effect Of Xcopri On Other Drugs

Table 5 summarizes the effect of Xcopri on other drugs.

Table 5: Pharmacokinetic Drug Interactions

Drug or Substrate TypeEffect of Xcopri on Drug or SubstrateClinical Recommendation
Antiepileptic Drugs
lamotrigine↓ plasma concentrationsBecause of a potential for reduced efficacy of these drugs, increase the dosage of lamotrigine or carbamazepine, as needed, when used concomitantly with Xcopri.
carbamazepine↓ plasma concentrations
phenytoin↑plasma concentrationsBecause of a potential 2-fold increase in phenytoin levels, gradually decrease phenytoin dosage by up to 50% as Xcopri is being titrated.
phenobarbital↑ plasma concentrationsBecause of a potential for an increase in the risk of adverse reactions from these drugs, consider a reduction in dosage of phenobarbital or clobazam, as clinically appropriate, when used concomitantly with Xcopri.
desmethylclobazam, the active metabolite of clobazam↑plasma concentrations
CYP2B6 Substrates↓ plasma concentrationsBecause of a potential for reduced efficacy of these drugs, increase the dosage of CYP2B6 or CYP3 A4 substrates, as needed, when used concomitantly with Xcopri.
CYP3A Substrates↓ plasma concentrations
Oral contraceptives↓ plasma concentrationsBecause of the potential for reduced efficacy of oral contraceptives, women should use additional or alternative non-hormonal birth control while taking Xcopri.
CYP2C19 Substrates↑ plasma concentrationsBecause of a potential for an increase in the risk of adverse reactions from these drugs, consider a reduction in dosage of CYP2C19 substrates, as clinically appropriate, when used concomitantly with Xcopri.

Drug That Shorten The QT Interval

  • Xcopri can shorten the QT interval; therefore, caution should be used when administering Xcopri and other drugs that shorten the QT interval.

CNS Depressants And Alcohol

  • Concomitant use of Xcopri with other CNS depressants, including alcohol, may increase the risk of neurological adverse reactions, including sedation and somnolence.

Is Xcopri safe to use while pregnant or breastfeeding?

  • There are no adequate data on the developmental risk associated with the use of Xcopri in pregnant women.
  • There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such as Xcopri, during pregnancy.
  • Encourage women who are taking Xcopri during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling the toll-free number 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/.

SLIDESHOW

Epilepsy: Symptoms, Causes and Treatment See Slideshow

Summary

Xcopri is a prescription medicine used to treat partial-onset seizures in adults. It is not known if Xcopri is safe and effective in children. Xcopri contains cenobamate and is listed as a Schedule V controlled substance.

Treatment & Diagnosis

Medications & Supplements

Subscribe to MedicineNet's General Health Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Medically Reviewed on 10/14/2020
References
All sections courtesy of the U.S. Food and Drug Administration
CONTINUE SCROLLING FOR RELATED SLIDESHOW